


Atrium Risk Targeted 7 Portfolio



As at 30 November 2025

Growth of \$100,000 since inception



● Portfolio ● Objective

Performance

	Portfolio	Objective
Since inception (% p.a.)	5.55%	5.46%
10 Years (%p.a.)		
7 Years (%p.a.)	5.91%	5.60%
5 Years (%p.a.)	5.90%	6.12%
3 Years (%p.a.)	7.95%	
1 Year	9.04%	
6 Months	6.49%	
3 Months	2.78%	
1 Month	-0.20%	

Objective refers to the Return objective as stated in the Key Facts table.

Source: Atrium Investment Management, Colonial First State. Inception date is 9 November 2016. Past performance is not a reliable indicator of future performance. Future performance and return of capital are not guaranteed. Performance figures are based on input data available as at the date of this report. Individual investor portfolio performance may be different from the results above and will differ among clients depending on the timing of their investment and the level of variation from the models. Performance is after fees and costs, assumes reinvestment of all distributions, is calculated using the highest annual fee tier, and does not take into account some or all of the rebates you may receive. Return objectives are internal return objectives which are measures that Atrium considers internally when managing the portfolio. Internal return objectives are not performance benchmarks and are not features set out in the PDS. Please refer to the managed account's Product Disclosure Statement (PDS) for more information on returns.



Superior



A rating is only one factor to be taken into account when deciding whether to invest.

Investment objective

To seek to maximise returns while managing portfolio volatility such that it does not exceed the Upper Risk Limit of 7% p.a. over rolling three (3) year time periods.

Investment strategy

Atrium's focus is on the level of risk within the portfolio. We seek to allocate to investments across a broad range of asset classes based on an assessment of their value and contribution to total risk and return.

Atrium can dynamically adjust the allocation to asset classes on an ongoing basis. By doing this, we seek to build a portfolio that can withstand changes in underlying market volatility.

The aim is to deliver a risk level in the Investment Portfolio that is consistent with the investment profile selected.

Key facts

Inception date	09 November 2016
Product code	CFSATRRMB7
Investment strategy	Diversified - Risk Targeted
Volatility limit (p.a.)	7.00%
Return objective	RBA Cash + 3.5%
Investment horizon	5 years
Liquidity	Daily [^]
Platform availability	CFS FirstWrap Plus

[^]Liquidity dependent on underlying holdings. Varies from daily to weekly.

Volatility & Sharpe Ratio

	10 Years	7 Years	5 Years	3 Years
Volatility (% p.a.)	-	5.07	4.15	3.94
Sharpe Ratio	-	1.22	0.78	0.94


What is volatility?

Volatility measures the fluctuations, or changes, in the price of an asset or market index. Assets with higher volatility generally have greater price changes, both positive and negative, and so higher volatility is generally an indication of higher risk.

What is the Sharpe Ratio?

The Sharpe Ratio measures returns relative to the volatility, or risk, that was taken to achieve that return. The higher the ratio, the better the risk-adjusted performance has been - in other words, the investment risks taken have delivered better returns to the portfolio.

Asset allocation



	Rates & credit	14.65%
	Cash	7.17%
	Australian equities	17.81%
	International equities	33.91%
	Listed infrastructure	2.87%
	Liquid alternatives	23.59%

Source: Atrium Investment Management. Asset allocations may change at any time. May not include all open futures or derivatives positions. Cash may include allocations to shorter term rates and credit investments that may, at times, be subject to capital volatility. Figures are based on input data available as at the date of this report. Due to rounding, numbers might not add up to 100%.

Atrium aims to achieve its investment objectives by investing across a range of asset classes on a global basis that provide exposure to different risk factors.

Each asset is included in the Portfolio for its ability to contribute to returns on a stand alone basis.

The investment universe comprises of 3 broad categories - Preservers, Growth Drivers and Diversifiers.



Preservers

Assets that protect the portfolio during periods of heightened equity market volatility and preserve capital, such as cash, government bonds and high quality investment grade bonds.



Growth Drivers

Assets that are expected to deliver higher rates of return over time with higher levels of associated volatility (risk). This predominantly comprises equities but also includes other assets that are highly correlated to equities such as listed property and infrastructure.



Diversifiers

Assets that generate additional real returns, with performance that is typically uncorrelated to the growth drivers and preservers within the portfolio. Importantly, they are a source of portfolio diversification away from equity market and interest rate risks, such as liquid alternatives and private markets.

Top holdings

Holding	Weight	Capital Position
RUSSELL IM - 30 STOCK FACTOR PORTFOLIO	11.22%	Australian equities
BETASHARES GLOBAL SHARES ETF	10.43%	International equities
CASH POSITION	7.17%	Cash
BETASHARES S&P 500 EQUAL WEIGHT ETF (HEDGED)	5.62%	International equities
COOLABAH ACTIVE COMPOSITE BOND ETF	5.61%	Rates & credit
MAN ALTERNATIVE RISK PREMIA	5.14%	Liquid alternatives
ANTIPODES GLOBAL FUND	4.87%	International equities
CROWN DIVERSIFIED MACRO	4.68%	Liquid alternatives
CROWN ATRIUM SEGREGATED PORTFOLIO	4.62%	Liquid alternatives
FAIRLIGHT GLOBAL SMALL & MID CAP FUND	3.72%	International equities

Source: Atrium Investment Management. Asset allocations may change at any time. May not include all open futures or derivatives positions. Cash may include allocations to shorter term rates and credit investments that may, at times, be subject to capital volatility. Holdings are based on input data available as at the date of this report.

Market update

Global markets were volatile in November but ended up slightly positive as mid-month fears over tech stock valuations and the viability of surging AI capex spending saw global stocks, and US stocks in particular, pummelled. By month end however, global risk assets had posted modest gains, supported by resilient growth and expectations of easier US monetary policy in 2026.

Developed market equities ended the month marginally positive, with Europe and parts of developed Asia outperforming the US as investors rotated toward markets more leveraged to falling bond yields and fiscal support. UK and Eurozone indices benefited from lower yields and ongoing fiscal measures. The US mega-cap tech names ended lower as did emerging market equities including China, which has been experiencing its own tech/AI, and new energy boom albeit in an economy which is

struggling for growth overall. Australian equities fell sharply with financials the weakest sector partly offset by the large exposure of the index to commodity related stocks which performed well as copper and gold prices rose.

Credit markets ended broadly flat with investment grade outperforming high yield as spreads drifted only modestly and fundamentals stayed supportive. Global rates markets continued to price a gradual easing cycle, led by the US Federal Reserve's earlier shift to cutting, while the ECB and Bank of Japan signalled steady but accommodative policy stances. The US dollar stayed broadly firm against major peers, which remained a headwind for unhedged offshore allocations in AUD terms.

For Australian investors, a key development was another upside surprise in monthly CPI, with headline inflation lifting to 3.8% year-on-year in October and trimmed mean to 3.3%, both back above the RBA's 2–3% target band. The RBA's November Statement on Monetary Policy acknowledged stronger-than-expected underlying inflation but judged domestic growth broadly on track, with GDP expected to run around its potential growth rate and unemployment drifting only slightly higher. The Board held the cash rate steady in November and reiterated a data-dependent stance, leaving markets to debate a low-probability further hike versus renewed cuts in 2026, a backdrop that argues for selective duration, quality credit and diversified global equity exposure in Australian portfolios.

Performance

The Portfolio declined in November as Australian equities ended lower in a month where global equities were roiled by fears over technology and AI stock prices relative to fundamentals. Global stocks rallied into month-end but tech stocks that have led markets higher throughout 2025 ended the month down. Liquid alternatives including gold provided a solid ballast in the face of volatility.

In equities, Antipodes Global Fund outperformed on European and Health sector exposures and an underweight to the US, while Hyperion Global Growth Companies Fund gave back some strong returns as the US tech sector fell over a volatile month. Smaller companies also declined in aggregate and Fairlight Global Small and Mid-cap Fund declined. Emerging markets allocations including the passive Vanguard ETF declined as Chinese indices fell sharply. In Australian equities, Firetrail Small Companies Fund outperformed, and the Australian Equity Managed Portfolio underperformed as Bendigo & Adelaide Bank fell on a weak trading update. Our allocations to listed real estate and infrastructure performed strongly for the month as investors sought defensive assets.

In liquid alternatives, a variety of diversifying strategies within the Atrium Alternatives Fund had strong returns including Man Alternative Risk Premia, One River Systematic Trend, and Crown Atrium Segregated Portfolio which benefited from stock picking in European materials and financials stocks. Crown Diversified Macro declined as long positions in energy markets including natural gas and crude oil fell.

Rates & credit allocations had mixed results for the month with the Atrium Enhanced Fixed Income Fund generating positive returns, while the Coolabah Active Composite Bond Fund declined as bond yields rose in response to higher inflation and expectations of higher Australian cash rates in the future.

Portfolio changes

During the month we reduced our exposure to Hyperion by half after a very strong run of alpha concentrated in a few US growth stocks including Tesla and Palantir. Overall equity exposure was maintained.

Outlook

We believe the Portfolio remains well diversified and positioned for global growth and a rotation from the more concentrated parts of equity benchmarks into smaller companies, emerging markets and quality stocks.

For more information

If you have any questions, please contact your Financial Adviser or www.atriuminvest.com.au

Important Information:

The information in this document (Information) has been prepared and issued by Atrium Investment Management Pty Ltd (ABN 17 137 088 745, AFSL 338634) ('Atrium' or 'Atrium Investment Management'). This Information is provided for the use of licensed and accredited financial advisers only. In no circumstances is it to be used by a potential client for the purposes of making a decision about a financial product or class of products. The Information is of a general nature only and does not take into account the objectives, financial situation or needs of any person. No liability is accepted for any loss or damage as a result of any reliance on the Information. Past performance is not a reliable indicator of future performance. Future performance and return of capital are not guaranteed.

The Trust Company (RE Services) Limited (ABN 45 003 278 831, AFSL 235150) is the Responsible Entity of the Colonial First State Separately Managed Account (ARSN 618 390 051) (CFS SMA). Investments in the CFS SMA are only available on CFS Edge. Investors should consider the Product Disclosure Statement (PDS) and Target Market Determination (TMD) before making any investment decisions. Applications for an investment in a portfolio in the CFS SMA can only be made pursuant to the application form attached to the relevant product disclosure statement or IDPS guide (CFS SMA Offer Documents). Please refer to the CFS SMA Offer Documents for important information concerning an investment in the CFS SMA.

SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. Information contained in this document attributable to SQM Research must not be used to make an investment decision. The SQM Research rating is valid at the time the report was issued, however it may change at any time. While the information contained in the rating is believed to be reliable, its completeness and accuracy is not guaranteed. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.